NYSEAMERICAN:NBYNovaBay Pharmaceuticals Stock Price, Forecast & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.01. The biopharmaceutical company had revenue of $1.89 million for the quarter. View NovaBay Pharmaceuticals' earnings history.

NovaBay Pharmaceuticals shares reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

1 Wall Street analysts have issued 12-month price objectives for NovaBay Pharmaceuticals' shares. Their forecasts range from $1.10 to $1.10. On average, they anticipate NovaBay Pharmaceuticals' stock price to reach $1.10 in the next twelve months. This suggests a possible upside of 1.9% from the stock's current price. View analysts' price targets for NovaBay Pharmaceuticals.

News headlines about NBY stock have trended negative on Sunday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 249,000 shares, an increase of 49.4% from the June 15th total of 166,700 shares. Based on an average trading volume of 4,260,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.3% of the company's stock are short sold. View NovaBay Pharmaceuticals' Current Options Chain.

Some companies that are related to NovaBay Pharmaceuticals include CorMedix (CRMD), 22nd Century Group (XXII), Ampliphi Biosciences (APHB), Ampio Pharmaceuticals (AMPE), Actinium Pharmaceuticals (ATNM), Helix Biopharma (HBP), Oncolytics Biotech (ONC), AquaBounty Technologies (AQB), Ibio (IBIO), Navidea Biopharmaceuticals (NAVB), Orgenesis (ORGS), Circassia Pharmaceuticals (CIR), Ampio Pharmaceuticals (AMPE), Novoheart (NVH) and Cocrystal Pharma (COCP). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Gilead Sciences (GILD), Novavax (NVAX), Inovio Pharmaceuticals (INO), Opko Health (OPK), Biocept (BIOC), Advanced Micro Devices (AMD), CorMedix (CRMD), Exelixis (EXEL), NVIDIA (NVDA) and Arbutus Biopharma (ABUS).

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NBY stock can currently be purchased for approximately $1.08.

NovaBay Pharmaceuticals has a market capitalization of $31.12 million. NovaBay Pharmaceuticals employs 70 workers across the globe.

The official website for NovaBay Pharmaceuticals is novabay.com.

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.